Kasia Rejniak: Bio & Abstract

BioMaths Colloquium Series – 2021/22
2 February 2022 – 3pm Online (register here for Zoom link)

Prof Kasia Rejniak

(Integrated Mathematical Oncology, Moffitt Cancer Centre, USA)

Micro-pharmacology: modeling the tissue barriers in drug delivery


Kasia Rejniak, Moffitt Cancer Center (USA)

Our BioMaths Colloquium Series continues with a seminar by Kasia Rejniak from the Integrated Mathematical Oncology department at the H. Lee Moffitt Cancer Center (Tampa, Florida). Kasia gained her MSc degree in Applied Mathematics and Computer Science from the University of Gdansk in Poland, and PhD degree form Tulane University in New Orleans, USA. She held postdoctoral positions at the Mathematical Biosciences Institute in Ohio, and University of Dundee in Scotland. She is currently Associate Member at the Integrated Mathematical Oncology Department at the Moffitt Cancer Center in Florida. Her main research interests involve use of computational and mathematical methods to study drug and metabolites delivery to tumour tissues, the impact of the tumour microenvironment on in its response to therapies, and optimisation of anti-cancer treatment schedules using histological data. She developed a suit of hybrid agent-based and fluid structure-interaction (microPKPD, MultiCell-LF, IBCell) models.



Systemic chemotherapy is one of the main anticancer treatments used for most kinds of clinically diagnosed tumors. However, the efficacy of these drugs can be hampered by the physical attributes of the tumor tissue, such as irregular vasculature, specific cellular and ECM architecture, metabolic gradients, or non-uniform expression of the cell membrane receptors. This can prevent therapeutic agents to reach tumor cells in quantities sufficient to exert the desired effect. To examine ways to improve drug delivery on a cell-to-tissue scale (single-cell pharmacology), we developed the micropharamcology computational framework that helps to design optimal combination drug schedules, optimal drug properties, or investigate the development of drug-induced resistance.

Comments are closed.